AbbVie (ABBV) Says Upadacitinib Met Primary and Key Efficacy Endpoints in Phase 2b/3 RA Study in Japanese Patients
Tweet Send to a Friend
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive results from the ongoing Phase 2b/3 SELECT-SUNRISE clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
